Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 6, 2023; 11(31): 7593-7609
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7593
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7593
Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer
Qing Yang, Li-Yuan Li, The Second Department of Oncology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China
Author contributions: Yang Q and Li LY contributed equally to this work; Yang Q and Li LY designed the study; Yang Q contributed to the analysis of the manuscript; Yang Q and Li LY were involved in the data and writing of this article; and all authors have read and approved the final manuscript.
Institutional review board statement: This study adopts network pharmacology and molecular docking simulation methods without requiring hospital ethical approval.
Informed consent statement: This study did not involve human experiments and does not require the signing of an informed consent form.
Conflict-of-interest statement: Yang Q and Li LY Declaration that there is no conflict of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qing Yang, MMed, Doctor, The Second Department of Oncology, The First Affiliated Hospital of Anhui University of Chinese Medicine, No. 117 Meishan Road, Hefei 230031, Anhui Province, China. cbdcnmyy929@sina.com
Received: August 23, 2023
Peer-review started: August 23, 2023
First decision: September 13, 2023
Revised: October 9, 2023
Accepted: October 23, 2023
Article in press: October 23, 2023
Published online: November 6, 2023
Processing time: 74 Days and 23.9 Hours
Peer-review started: August 23, 2023
First decision: September 13, 2023
Revised: October 9, 2023
Accepted: October 23, 2023
Article in press: October 23, 2023
Published online: November 6, 2023
Processing time: 74 Days and 23.9 Hours
Core Tip
Core Tip: The network pharmacological and molecular docking study of Liu-Wei-Bu-Qi capsule (LBC) on lung cancer revealed that LBC’s active ingredients target multiple signaling pathways, including the endothelial growth factor, toll-like receptor, prolactin, FoxO, PI3K-Akt, and HIF-1 pathways. Quercetin, found in LBC, showed promising affinity for MAPK3, highlighting its potential role in lung cancer treatment. These findings provide valuable insights into the mechanisms of action of LBC and pave the way for further investigations into its therapeutic effects on lung cancer.